Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

NCT04677777 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

BIOLOGICAL: PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)

Sponsor

Prolong Pharmaceuticals